TOP TEN perturbations for 40101_g_at (Homo sapiens)
Organism: Homo sapiens
Gene: 40101_g_at
Selected probe(set): 209435_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 40101_g_at (209435_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
prostate cancer study 8 (p. canc) / prostate cancer study 8 (ptasc)
Relative Expression (log2-ratio):-2.766428Number of Samples:3 / 2
| Experimental | prostate cancer study 8 (p. canc) |
| CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy. | |
| Control | prostate cancer study 8 (ptasc) |
| CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy. |
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-2.6711645Number of Samples:3 / 3
| Experimental | echinomycin study 1 |
| Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
| Control | deferoxamine study 5 |
| Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Relative Expression (log2-ratio):2.611229Number of Samples:3 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. |
diclofenac study 6 (55uM) / vehicle (PBS) treated HepG2 sample
Relative Expression (log2-ratio):2.4854145Number of Samples:3 / 12
| Experimental | diclofenac study 6 (55uM) |
| HepG2 cells treated with compound: diclofenac (55uM; CAS no.:15307-86-5) for 24 hours. Diclofenac is hepatotoxic and may cause necrosis. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:, , | |
| Control | vehicle (PBS) treated HepG2 sample |
| HepG2 cells treated with PBS (0.5% v/v) as solvent control for 24 hours. |
ciclosporin study 6 (20uM) / vehicle (DMSO) treated HepG2 sample
Relative Expression (log2-ratio):2.254941Number of Samples:3 / 21
| Experimental | ciclosporin study 6 (20uM) |
| HepG2 cells treated with compound: cyclosporine A (INN: ciclosporin; 20uM; CAS no.:59865-13-3) for 24 hours. Ciclosporin is hepatotoxic and may cause cholestasis. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:, | |
| Control | vehicle (DMSO) treated HepG2 sample |
| HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours. |
cysteine deprivation study 1 (long) / non-deprivated C3A/HepG2 cell sample
Relative Expression (log2-ratio):2.2446966Number of Samples:3 / 3
| Experimental | cysteine deprivation study 1 (long) |
| C3A/HepG2 cells were cultured in sulfur amino acid-free DMEM supplemented only with 0.1 mM methionine (cysteine-free medium) for 42h. | |
| Control | non-deprivated C3A/HepG2 cell sample |
| C3A/HepG2 cells were cultured in sulfur amino acid-free DMEM supplemented with 0.1 mM methionine + 0.1 mM cysteine (complete medium) for 42h. |
tetracycline study 7 (2000uM) / vehicle (DMSO) treated HepG2 sample
Relative Expression (log2-ratio):2.228568Number of Samples:3 / 21
| Experimental | tetracycline study 7 (2000uM) |
| HepG2 cells treated with compound: tetracycline (2000uM; CAS no.:60-54-8) for 24 hours. Tetracycline is hepatotoxic and may cause steatosis. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:, , , , , | |
| Control | vehicle (DMSO) treated HepG2 sample |
| HepG2 cells treated with DMSO (0.5% v/v) as solvent control for 24 hours. |
stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Relative Expression (log2-ratio):2.206543Number of Samples:3 / 4
| Experimental | stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. | |
| Control | stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast) |
| Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation. |
pancreatic islet study 3 (re-differentiated; PPRF; 4d) / normal pancreatic islet sample
Relative Expression (log2-ratio):2.1913624Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 4d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 4 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |
pancreatic islet study 3 (re-differentiated; PPRF; 8d) / normal pancreatic islet sample
Relative Expression (log2-ratio):2.1550493Number of Samples:2 / 7
| Experimental | pancreatic islet study 3 (re-differentiated; PPRF; 8d) |
| Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 8 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0 ug/ml. | |
| Control | normal pancreatic islet sample |
| Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation. |